GB2547494B - Monovalent H5 vaccine - Google Patents

Monovalent H5 vaccine Download PDF

Info

Publication number
GB2547494B
GB2547494B GB1612451.3A GB201612451A GB2547494B GB 2547494 B GB2547494 B GB 2547494B GB 201612451 A GB201612451 A GB 201612451A GB 2547494 B GB2547494 B GB 2547494B
Authority
GB
United Kingdom
Prior art keywords
vaccine
monovalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1612451.3A
Other versions
GB2547494A (en
GB201612451D0 (en
Inventor
He Fang
Jimmy Kwang Hwei-Sing
Mookkan Prabakaran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temasek Life Sciences Laboratory Ltd
Original Assignee
Temasek Life Sciences Laboratory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temasek Life Sciences Laboratory Ltd filed Critical Temasek Life Sciences Laboratory Ltd
Publication of GB201612451D0 publication Critical patent/GB201612451D0/en
Publication of GB2547494A publication Critical patent/GB2547494A/en
Application granted granted Critical
Publication of GB2547494B publication Critical patent/GB2547494B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/11Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171Demonstrated in vivo effect

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
GB1612451.3A 2013-12-23 2014-12-12 Monovalent H5 vaccine Active GB2547494B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920187P 2013-12-23 2013-12-23
PCT/SG2014/000594 WO2015099609A1 (en) 2013-12-23 2014-12-12 Monovalent h5 vaccine

Publications (3)

Publication Number Publication Date
GB201612451D0 GB201612451D0 (en) 2016-08-31
GB2547494A GB2547494A (en) 2017-08-23
GB2547494B true GB2547494B (en) 2020-05-20

Family

ID=53479314

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1612451.3A Active GB2547494B (en) 2013-12-23 2014-12-12 Monovalent H5 vaccine

Country Status (5)

Country Link
US (1) US9694067B2 (en)
CN (1) CN106029686B (en)
GB (1) GB2547494B (en)
SG (1) SG11201604996XA (en)
WO (1) WO2015099609A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113260378B (en) * 2018-11-06 2024-06-07 勃林格殷格翰动物保健有限公司 Immunogenic compositions against avian influenza virus H5 subtype

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033105A1 (en) * 2006-09-13 2008-03-20 Dso National Laboratories Hemagglutinin antibody and uses thereof
WO2011136738A1 (en) * 2010-04-30 2011-11-03 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083533A1 (en) * 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed PROTEINS OF HEMAGLUTININ 5 (H5) FOR THE TREATMENT AND PREVENTION OF INFLECTIONS OF FLU

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033105A1 (en) * 2006-09-13 2008-03-20 Dso National Laboratories Hemagglutinin antibody and uses thereof
WO2011136738A1 (en) * 2010-04-30 2011-11-03 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Antiviral Research, Vol. 105, 2014, F He, et al., "Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice", pages 143-151. *

Also Published As

Publication number Publication date
GB2547494A (en) 2017-08-23
GB201612451D0 (en) 2016-08-31
WO2015099609A1 (en) 2015-07-02
CN106029686B (en) 2019-09-10
US20170000877A1 (en) 2017-01-05
CN106029686A (en) 2016-10-12
US9694067B2 (en) 2017-07-04
SG11201604996XA (en) 2016-07-28

Similar Documents

Publication Publication Date Title
IL276210B1 (en) Mers-cov vaccine
IL279395A (en) Vaccine composition
HK1226440A1 (en) Cmv vaccines
HRP20181376T1 (en) Improved poxviral vaccines
HK1219980A1 (en) Vascular-targeted -cell herapy
ZA201508642B (en) Malaria vaccine
GB201315946D0 (en) Oncology vaccine
HK1218872A1 (en) Hepatitis b vaccine
GB201318084D0 (en) Malaria vaccination
GB201301085D0 (en) Glycoconjugate Vaccine
EP2992813A4 (en) Liquid-testing implement
EP2923945A4 (en) Ornithopter
EP2952799A4 (en) Pipe-reinforcing implement
HK1217206A1 (en) Vaccine
EP2923944A4 (en) Ornithopter
GB201309664D0 (en) Fish vaccine
GB201301119D0 (en) Viral vaccines
GB2547494B (en) Monovalent H5 vaccine
HK1216149A1 (en) Campylobacter vaccine
EP2997818A4 (en) Cultivation device
GB201320646D0 (en) Vaccine
GB201315556D0 (en) Vaccine
GB201320421D0 (en) Conjugated vaccine
GB201404235D0 (en) Bakeware
IL226881A (en) Mailbox apparatus

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1238256

Country of ref document: HK